Halozyme Therapeutics (HALO) FCF Margin Growth (3y) (2013 - 2026)

Halozyme Therapeutics (HALO) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -1,272.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -2,228.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9,545.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.75 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -3,088.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4,612.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 14,060.00
10 Halozyme Therapeutics 11.25 Bn 11.02 Bn 401.83 Mn 1,824.00

Historic Data

Download Data
DateValue
Jun 30, 2026 1,824.00
Mar 31, 2026 -658.00
Dec 31, 2025 403.00
Sep 30, 2025 1,672.00
Jun 30, 2025 449.00
Mar 31, 2025 1,738.00
Dec 31, 2024 -1,974.00
Sep 30, 2024 -6,736.00
Jun 30, 2024 -121.00
Mar 31, 2024 -92.00
Dec 31, 2023 -433.00
Sep 30, 2023 5,303.00
Jun 30, 2023 2,381.00
Mar 31, 2023 7,387.00
Dec 31, 2022 9,340.00
Sep 30, 2022 9,242.00
Jun 30, 2022 9,431.00
Mar 31, 2022 4,861.00
Dec 31, 2021 6,428.00
Sep 30, 2021 18,470.00